ZyVersa Therapeutics, Inc. (ZVSA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US98987D3008
ZyVersa Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -25.49 m USD |
| EBIT | -25.80 m USD |
| Net income | -24.95 m USD |
| Diluted EPS – continuing operations | -4.18 USD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100 a humanized monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of numerous inflammatory diseases, with cardiometabolic conditions associated with obesity as the lead. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.
More stocks
- Solidus Communications, Inc. (SLDC)
- PetroGas Co (PTCO)
- Direct Digital Holdings, Inc. (DRCT)
- AMERIGUARD SECURITY SERVICES, INC. (AGSS)
- KIDZ AI Inc. (KIDZ)
- Freight Technologies, Inc. (FRGT)
- OZOP ENERGY SOLUTIONS, INC. (OZSC)
- ZeroStack Corp. (ZSTK)
- SOCIETY PASS INCORPORATED. (SOPAQ)
- WINDTREE THERAPEUTICS INC /DE/ (WINT)
- IO Biotech, Inc. (IOBTQ)
- Bespoke Extracts, Inc. (BSPK)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.